Sex Differences in Ketamine Antidepressant Effects

氯胺酮抗抑郁作用的性别差异

基本信息

  • 批准号:
    9036446
  • 负责人:
  • 金额:
    $ 38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-06-21 至 2018-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Current medications for major depression suffer from numerous limitations. Once the right drug for treatment has been determined, it will still take several weeks for it to take effect and improve mood. This time lag has been a serious concern for the healthcare community when dealing with patients with suicidal thoughts. However, recent clinical studies have shown that a single low-dose injection of ketamine, an N-methyl d-aspartate receptor (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting, even in patients who do not respond well to various other anti-depressants. In preclinical studies, the mammalian target of rapamycin (mTOR) in the medial prefrontal cortex (mPFC) and the eukaryotic elongation factor (eEF2) in the hippocampus have been proposed as critical mediators of ketamine rapid antidepressant actions. However, so far, all studies examining the rapid antidepressant effects of ketamine have focused on male subjects. This is very surprising in light of the fact that major depression affects twice as many women as men. Thus, it is especially important to determine whether the same doses of ketamine that are beneficial in male subjects will be efficient in female subjects as well. It is aso important to determine whether the antidepressant effects of ketamine in female rats will implicate the same molecular pathways described in male rats (mTOR in the mPFC and/or eEF2 in the hippocampus) and determine if gonadal hormones, and in particular 17 ¿ -estradiol (E2) and its receptors (ER¿ and/or ER¿), play a role in these effects (in view of the large literature showing interactions between estrogen and the downstream signaling of the NMDAR). Our preliminary data showed that female rats are more sensitive to ketamine antidepressant effects when compared to male rats; a low dose of ketamine (2.5 mg/kg), that is not antidepressant in males, had clear and long-term antidepressant effects in female rats. Excitedly, the antidepressant effects of this low dose of ketamine were completely abolished when female rats were ovariectomized. This effect was completely reversed when E2 benzoate (E2B) -but not progesterone (P4) - was supplemented, suggesting a role for E2 at enhancing the antidepressant effects of ketamine in female rats. Accordingly, in this application we will tes the general hypothesis that gonadal E2 plays a major role in sex differences in the antidepressant effects of ketamine.
描述(由申请人提供):目前治疗重度抑郁症的药物有许多局限性。一旦确定了正确的治疗药物,它仍然需要几个星期才能生效并改善情绪。在处理有自杀想法的患者时,这种时间滞后一直是医疗保健界的一个严重问题。然而,最近的临床研究表明,单次低剂量注射氯胺酮(一种N-甲基d-天冬氨酸受体(NMDAR)拮抗剂)具有快速的抗抑郁作用,可在数小时内观察到,并且持续时间长,即使在对各种其他抗抑郁药反应不佳的患者中也是如此。在临床前研究中,内侧前额叶皮质(mPFC)中的哺乳动物雷帕霉素靶蛋白(mTOR)和海马中的真核细胞延伸因子(eEF 2)已被认为是氯胺酮快速抗抑郁作用的关键介质。然而,到目前为止,所有研究氯胺酮的快速抗抑郁作用的研究都集中在男性受试者身上。这是非常令人惊讶的,因为严重抑郁症影响的女性是男性的两倍。因此,确定在男性受试者中有益的相同剂量的氯胺酮是否在女性受试者中也有效尤为重要。阿索重要的是确定氯胺酮在雌性大鼠中的抗抑郁作用是否涉及在雄性大鼠中描述的相同分子途径(mPFC中的mTOR和/或海马中的eEF 2),并确定性腺激素,特别是17 <$-雌二醇(E2)及其受体雌激素受体(ER)和/或雌激素受体(ER)在这些效应中起作用(鉴于大量文献显示雌激素与NMDAR下游信号传导之间的相互作用)。我们的初步数据表明,与雄性大鼠相比,雌性大鼠对氯胺酮抗抑郁作用更敏感;低剂量氯胺酮(2.5 mg/kg)在雄性中不具有抗抑郁作用,但在雌性大鼠中具有明确的长期抗抑郁作用。令人兴奋的是,当雌性大鼠卵巢切除后,这种低剂量氯胺酮的抗抑郁作用完全消失。当补充E2苯甲酸盐(E2 B)而不是孕酮(P4)时,这种作用完全逆转,表明E2在增强氯胺酮在雌性大鼠中的抗抑郁作用方面的作用。因此,在本申请中,我们将测试性腺E2在氯胺酮抗抑郁作用的性别差异中起主要作用的一般假设。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MOHAMED KABBAJ其他文献

MOHAMED KABBAJ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MOHAMED KABBAJ', 18)}}的其他基金

Breaking bonds in prairie voles
打破草原田鼠的束缚
  • 批准号:
    10373253
  • 财政年份:
    2022
  • 资助金额:
    $ 38万
  • 项目类别:
Breaking bonds in prairie voles
打破草原田鼠的束缚
  • 批准号:
    10581709
  • 财政年份:
    2022
  • 资助金额:
    $ 38万
  • 项目类别:
Neurobiology of Ketamine Addiction
氯胺酮成瘾的神经生物学
  • 批准号:
    10229544
  • 财政年份:
    2018
  • 资助金额:
    $ 38万
  • 项目类别:
Neurobiology of Ketamine Addiction
氯胺酮成瘾的神经生物学
  • 批准号:
    10471826
  • 财政年份:
    2018
  • 资助金额:
    $ 38万
  • 项目类别:
Epigenetics of social bonding in prairie voles
草原田鼠社会联系的表观遗传学
  • 批准号:
    9489311
  • 财政年份:
    2016
  • 资助金额:
    $ 38万
  • 项目类别:
Sex Differences in Ketamine Antidepressant Effects
氯胺酮抗抑郁作用的性别差异
  • 批准号:
    8826814
  • 财政年份:
    2013
  • 资助金额:
    $ 38万
  • 项目类别:
Sex Differences in Ketamine Antidepressant Effects
氯胺酮抗抑郁作用的性别差异
  • 批准号:
    8583138
  • 财政年份:
    2013
  • 资助金额:
    $ 38万
  • 项目类别:
Sex Differences in Ketamine Antidepressant Effects
氯胺酮抗抑郁作用的性别差异
  • 批准号:
    9247036
  • 财政年份:
    2013
  • 资助金额:
    $ 38万
  • 项目类别:
Sex Differences in Ketamine Antidepressant Effects
氯胺酮抗抑郁作用的性别差异
  • 批准号:
    8686960
  • 财政年份:
    2013
  • 资助金额:
    $ 38万
  • 项目类别:
Sex Differences In Anxiety: Role of Zif268
焦虑中的性别差异:Zif268 的作用
  • 批准号:
    8425081
  • 财政年份:
    2010
  • 资助金额:
    $ 38万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了